These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 29525934)

  • 1. Pleiotropic Anti-atherosclerotic Effects of PCSK9 InhibitorsFrom Molecular Biology to Clinical Translation.
    Karagiannis AD; Liu M; Toth PP; Zhao S; Agrawal DK; Libby P; Chatzizisis YS
    Curr Atheroscler Rep; 2018 Mar; 20(4):20. PubMed ID: 29525934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PCSK9 Biology and Its Role in Atherothrombosis.
    Barale C; Melchionda E; Morotti A; Russo I
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 and atherosclerosis: Looking beyond LDL regulation.
    Ragusa R; Basta G; Neglia D; De Caterina R; Del Turco S; Caselli C
    Eur J Clin Invest; 2021 Apr; 51(4):e13459. PubMed ID: 33236356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
    Hadjiphilippou S; Ray KK
    Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PCSK9 and inflammation: a review of experimental and clinical evidence.
    Momtazi-Borojeni AA; Sabouri-Rad S; Gotto AM; Pirro M; Banach M; Awan Z; Barreto GE; Sahebkar A
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):237-245. PubMed ID: 31236571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia.
    Tziomalos K
    Curr Pharm Des; 2017; 23(10):1495-1499. PubMed ID: 28155622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9): Impact of PCSK9 on Major Adverse Cardiac and Cerebrovascular Events.
    Akin M; Skripuletz T; Napp LC; Berliner D; Akin I; Haghikia A; Akin E; Bauersachs J
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):94-100. PubMed ID: 27470008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K; Reinecke H
    Vasa; 2018 Apr; 47(3):165-176. PubMed ID: 29412075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future role of proprotein convertase subtilisin/kexin type 9 inhibitors in preventive cardiology.
    Mahmood T; Shapiro MD
    Curr Opin Cardiol; 2019 Sep; 34(5):519-525. PubMed ID: 31246589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease.
    Bittner VA; Giugliano RP; Brinton EA; Guyton JR
    J Clin Lipidol; 2018; 12(4):835-843. PubMed ID: 30055750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Research progress on alternative non-classical mechanisms of PCSK9 in atherosclerosis in patients with and without diabetes.
    Tang Y; Li SL; Hu JH; Sun KJ; Liu LL; Xu DY
    Cardiovasc Diabetol; 2020 Mar; 19(1):33. PubMed ID: 32169071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDLCholesterol.
    Wang Y; Liu ZP
    Mini Rev Med Chem; 2019; 19(2):165-176. PubMed ID: 29692249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of PCSK9 in lipid metabolism and atherosclerosis.
    Lin XL; Xiao LL; Tang ZH; Jiang ZS; Liu MH
    Biomed Pharmacother; 2018 Aug; 104():36-44. PubMed ID: 29758414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol-Lowering Agents.
    Rosenson RS; Hegele RA; Koenig W
    Circ Res; 2019 Feb; 124(3):364-385. PubMed ID: 30702994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-PCSK9 antibodies inhibit pro-atherogenic mechanisms in APOE*3Leiden.CETP mice.
    Schuster S; Rubil S; Endres M; Princen HMG; Boeckel JN; Winter K; Werner C; Laufs U
    Sci Rep; 2019 Jul; 9(1):11079. PubMed ID: 31366894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging biologic therapies for hypercholesterolaemia.
    Pucci G; Cicero AF; Borghi C; Schillaci G
    Expert Opin Biol Ther; 2017 Sep; 17(9):1077-1087. PubMed ID: 28617192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9-inhibition across different patient populations.
    Stürzebecher PE; Laufs U
    Curr Opin Lipidol; 2024 Aug; 35(4):179-186. PubMed ID: 38547336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PCSK9 inhibition and inflammation: A narrative review.
    Ruscica M; Tokgözoğlu L; Corsini A; Sirtori CR
    Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway.
    Tang ZH; Peng J; Ren Z; Yang J; Li TT; Li TH; Wang Z; Wei DH; Liu LS; Zheng XL; Jiang ZS
    Atherosclerosis; 2017 Jul; 262():113-122. PubMed ID: 28535426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.